

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virgiria 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/833,005	04/12/2001	Douglas A. Hardy	GE04591	9509
Stanley A. Sch	7590 07/17/200 ditter	8	EXAM	IINER
JENNER & BLOCK, LLC			SHIFERAW, ELENI A	
One IBM Plaz Chicago, IL 60			ART UNIT	PAPER NUMBER
			2136	
			MAIL DATE	DELIVERY MODE
			07/17/2008	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Notice of Abandonment	09/833.005 HARDY		/ ET AL.				
Notice of Abandonment	Examiner	Art Unit					
	ELENI A. SHIFERAW	2136					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
This application is abandoned in view of:							
Applicant's failure to timely file a proper reply to the Office letter mailed on <u>04 October 2007</u> .  (a) A reply was received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply (including a total extension of time of month(s)) which expired on							
(b) A proposed reply was received on, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection.							
(A proper reply under 37 CFR 1.113 to a final rejection consists only of; (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compiliance with 37 CFR 1.114).							
(c) A reply was received on but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).							
(d) ☑ No reply has been received.							
2. Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85). (a) The issue fee and publication fee, if applicable, was received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).							
(b) The submitted fee of is insufficient. A balance of is due.							
The issue fee required by 37 CFR 1.18 is \$ The publication fee, if required by 37 CFR 1.18(d), is \$							
(c) The issue fee and publication fee, if applicable, has not been received.							
<ol> <li>Applicant's failure to timely file corrected drawings as requested.</li> <li>Allowability (PTO-37).</li> </ol>	uired by, and within the three-month p	period set in, the No	otice of				
(a) Proposed corrected drawings were received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply.							
(b) $\square$ No corrected drawings have been received.							
<ol> <li>The letter of express abandonment which is signed by the the applicants.</li> </ol>	e attorney or agent of record, the ass	ignee of the entire i	nterest, or all of				
<ol> <li>The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.</li> </ol>							
. The decision by the Board of Patent Appeals and Interference rendered on and because the period for seeking court review of the decision has expired and there are no allowed claims.							
7. The reason(s) below:							

/Nasser G Moazzami/ Supervisory Patent Examiner, Art Unit 2136

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.

U.S. Patent and Trademark Office
PTOL-1432 (Rev. 04-01)